About SOMAÍ
compassionate care scientifically crafted
Our company is dedicated to formulating innovative cannabis-based products to ensure a healthy and comfortable life. For that, we create a wide variety of medications for chronic patients and different conditions. We aim to design calm and satisfactory experience of administering, prescribing and purchasing cannabis-based medicine.
SOMAÍ Pharmaceuticals is an EU-GMP European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal, and distributing EU GMP-certified cannabinoid-containing pharmaceuticals globally. SOMAÍ emphasizes scientific pharmacology applications with EU-GMP standards to effectively and consistently deliver treatments to the endocannabinoid system across all markets.
Our Product Categories
For patients
FOR HEALTHCARE PROFESSIONALs
For partners
Company News
Cosma S.A. and SOMAÍ Pharmaceuticals partner to Revolutionize Poland with the most Innovative Cannabis-Based Solutions
Cosma S.A., a leader in cannabis-based pharmaceutical advancements, and SOMAÍ Pharmaceuticals, a fully vertically integrated Multi-Country Operator (MCO)…
Read more
SOMAÍ Pharmaceuticals Expands Its Most Comprehensive Medicinal Cannabis Portfolio With Launch of New Mint Oral Solutions Line
SOMAÍ Pharmaceuticals is proud to announce the Mint Oral Solutions product line launch in Australia, Germany, and the…
Read more
Leading Canadian Cannabis Brand Ghost Drops Enters into an Agreement with SOMAÍ Group for Global Distribution
The partnership opportunely positions Ghost Drops and SOMAÍ Group to succeed in the EU, UK, and Australian Cannabis…
Read more
SOMAÍ Pharmaceuticals Introducing the U.S. Award-Winning Airo Brand to European and Australian Markets
SOMAÍ Pharmaceuticals announces its partnership with AIRO BRANDS, a U.S. multi-state CPG company focused on proprietary cannabis products….
Read more
SOMAÍ Pharmaceuticals and Canify Announce Their Partnership to Introduce a Cannabinoid-Based Product Line in Germany
SOMAÍ Pharmaceuticals announces a landmark three-year marketing & distribution agreement with Canify AG. This partnership signifies SOMAÍ Pharmaceuticals’…
Read more
SOMAÍ Pharmaceuticals Enters German Market with Strategic Partnerships Securing €10 Million 2-year Distribution Deal
SOMAÍ Pharmaceuticals announces its entry into the German market through partnerships with Canymed GmbH and Grünhorn, securing a…
Read More
SOMAÍ Pharmaceuticals Partners with UK’s largest medical cannabis study T21 by Drug Science
SOMAÍ Pharmaceuticals is thrilled to announce partnering with the groundbreaking medical cannabis study, T21 (formerly Project TWENTY21). As…
read more
SOMAÍ Pharmaceuticals Signs Manufacturing Contract with Canna Forest
SOMAÍ Pharmaceuticals has signed a manufacturing agreement with Canna Forest to produce EU-GMP-certified extracted cannabis APIs and products…
read more
SOMAÍ Pharmaceuticals Receives EU-GMP Certification and Raises €5 million
SOMAÍ Pharmaceuticals Unipessoal LDA, the largest European pharmaceutical cannabis product manufacturer, is pleased to announce that it has…
Read more
SOMAÍ Pharmaceuticals has renewed the partnership with Lusófona University/CBIOS for formulation development
According to this partnership, Lusófona will develop lab-scale formulations and perform corresponding stability testing. The collaboration will also…
Read more
SOMAÍ Pharmaceuticals Signs Supply Contract with Cosma Cannabis
SOMAÍ Pharmaceuticals has entered into a two-year supply agreement with a well-respected Polish distributor Cosma Cannabis. Cosma produces…
Read more
Clever Leaves Partners with SOMAÍ Pharmaceuticals and Sends First Commercial Shipments to Portugal
SOMAÍ Pharmaceuticals Unipessoal LDA has entered into a five-year agreement with Clever Leaves Holdings Inc., a global medicinal…
Read more